

PATENT
269/084

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Christopher G. M. Ken, et al.

Serial No.: 09/523,585

Filed: March 10, 2000

**For: DETACHABLE ANEURYSM NECK
BRIDGE (III)**

)
) **Group Art Unit: 3731**

)
) **Examiner: G. Phanijphand**

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination of this application on the merits, please amend the application as follows:

IN THE CLAIMS

Please cancel claims 17 through 30, and add new claims 31 through 44 as follows:

31. An implantable retainer, deliverable via an elongate tubular delivery device for retaining vaso-occlusive device in an aneurysm, comprising:
- (a) a core wire having a proximal end and a distal end,
 - (b) a joint extending between the distal end of the core wire and at least one array element, said joint being electrolytically severable upon application of a suitable current to said joint, said joint being comparatively more susceptible to electrolytic severability than said core wire and said at least one array element, and
 - (c) a retainer assembly comprising said at least one array element, said retainer assembly having a first delivery shape when retained within said elongate tubular delivery device and having a distal delivery end and a proximal delivery end, and a second deployed shape, different

SJ #46516.2

PATENT
269/084

than first delivery shape when said retainer assembly is not retained within said tubular delivery device and having a distal deployed and an proximal deployed end, said at least one array element extending outwardly from said joint in said second deployed shape, and wherein after electrolytic severance from said core wire said retainer assembly includes a residual joint.

32. The implantable retainer of claim 31, wherein said core wire is covered with an electrical insulation layer from near its proximal end to near its distal end.

33. The implantable retainer of claim 31, wherein said at least one array element comprises platinum.

34. The implantable retainer of claim 31, wherein said at least one array element comprises tantalum.

35. The implantable retainer of claim 31, wherein said at least one array element comprises stainless steel.

36. The implantable retainer of claim 31, wherein said at least one array element comprises a super-elastic alloy.

37. The implantable retainer of claim 31, wherein at least a portion of said at least one array element is covered by radio-opaque material.

38. The implantable retainer of claim 37, wherein said radio-opaque material is platinum.

39. The implantable retainer of claim 31, wherein when said retainer assembly is in said second deployed shape, each of said at least one array element terminates remotely from said joint.

40. The implantable retainer of claim 31, wherein when said retainer assembly is in said second deployed shape said residual joint is distal to said proximal deployed end.

SI #46516.2

PATENT
269/084

41. The implantable retainer of claim 31, wherein when said retainer assembly is in said second deployed shape said residual joint is on said proximal deployed end.

42. The implantable retainer of claim 31, wherein said proximal deployed end is distal to said proximal delivery end when the retainer assembly is in the second deployed shape.

43. The implantable retainer of claim 31, wherein said secondary form approximates the shape of a vascular aneurysm.

44. The implantable retainer of claim 31, wherein said retainer assembly encloses a volume and wherein said implantable retainer contains a helically wound vaso-occlusive device.

REMARKS

Applicants respectfully request that the foregoing amendments be entered before examination of the above-identified application. The new claims add no new matter to the pending application. All claims copied from U.S. Patent 5,916,235 have been cancelled. Applicants hereby withdraw their prior request for an interference with U.S. Patent 5,916,235.

If the Examiner has any questions or comments regarding this amendment, a telephone call to the undersigned at the number listed below is respectfully urged.

Respectfully submitted,
LYON & LYON LLP

Dated: 7-3-02
633 West Fifth Street, Suite 4700
Los Angeles, California 90071-2066
(408) 993-1555
(408) 287-2664 fax

By: DTB
David T. Burse
Reg. No. 37,104

SJ #46516.2

LYON & LYON LLP
A LIMITED LIABILITY PARTNERSHIP
INCLUDING PROFESSIONAL CORPORATIONS
333 West San Carlos Street, Suite 800
San Jose, California 95110
Phone: (408) 993-1555
Fax: (408) 287-2664

FACSIMILE TRANSMITTAL FORM

To: Gwen Phanijphand, Examiner	Fax Number: 703-746-9125	Phone Number: 703-305-4845
From: David T. Burse	Fax Number: 408-287-2664	Phone Number: 408-993-1555
Re: Preliminary Amendment to App. 09/523,585	Date/Time sent: 7/3/02 3:36 PM	No. of Pages: 4 (incl. cover)
Client Name: Target Therapeutics	Client Matter No.: 02690842	

Notes/Comments:

In accordance with our teleconference this afternoon, please find enclosed a Preliminary Amendment indicating the amended claims we discussed over the phone. Thank you.

TO BE COMPLETED BY FAX OPERATOR

TIME TRANSMITTED: _____ TRANSMITTED BY: _____

This transmittal is intended only for the use of the individual or entity to which it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this transmittal is not the intended recipient or the employee or agent responsible for delivering the transmittal to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone, and return the original message to us by mail at the above address. Thank you.